Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Committee backs study and narrow path for supervised psychedelics clinical trials
Summary
The committee recommended HB1693 for future legislation to permit narrowly defined, medically supervised clinical trials and research on certain Schedule I psychedelics; members stressed the research should be limited and supervised within medical settings.
The committee recommended HB1693, which would permit narrowly tailored clinical research and supervised therapeutic use of specific psychedelics, emphasizing medical oversight and limits to protect patients.
Representative Leon and others noted expanding clinical evidence and FDA 'breakthrough therapy' designations for certain compounds and said the…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
